SlidesetViral Hepatitis and Liver DiseaseOpening lecture: A pathologist, a radiologist and a hepatologist walked into a bar- Brent Neuschwander-Tetri, MDView Slideset
SlidesetViral Hepatitis and Liver DiseaseInnovation in histological assessment of NASH- Pierre Bedossa, MD, PhDView Slideset
SlidesetViral Hepatitis and Liver DiseaseSession 2: Pathways to biomarker qualification and acceptance- Chris Leptak, MD, PhDView Slideset
SlidesetViral Hepatitis and Liver DiseaseCollaboration in action - Foundation for the National Institutes of Health- Roberto Calle, MD, FACE, FACPView Slideset
SlidesetViral Hepatitis and Liver DiseaseCollaboration in action - Innovative Medicines Initiative- Quentin Anstee, BSc, MB BS, PhD, MRCP(UK), FRCPView Slideset
SlidesetViral Hepatitis and Liver DiseaseCirculating nucleic acids and combination panels- Sven Francque, MD, PhDView Slideset
SlidesetViral Hepatitis and Liver DiseaseRole of genetic assessments- Quentin Anstee, BSc, MB BS, PhD, MRCP(UK), FRCPView Slideset
SlidesetViral Hepatitis and Liver DiseaseHepatic proton density fat fraction correlates with histologic measures of steatosis and is responsive to change in those measures in a multi-center nonalcoholic steatohepatitis clinical trial- Michael MiddletonView Slideset
SlidesetViral Hepatitis and Liver DiseaseA meta-analysis on repeatability of magnetic resonance elastography of liver- Suraj SeraiView Slideset
SlidesetViral Hepatitis and Liver DiseaseTransient elastography & other techniques- Raj Vuppalanchi, MBBSView Slideset
SlidesetViral Hepatitis and Liver DiseasePrinciples of kinetic measures- Greg Everson, MD, FACPView Slideset
SlidesetViral Hepatitis and Liver DiseaseNovel multiparametric magnetic resonance elastography (MRE) protocol accurately predicts NAS score for NASH diagnosis- Alina AllenView Slideset
SlidesetViral Hepatitis and Liver DiseaseBig data vs. the individual liver - regulatory perspective- Robert Schuck, PharmD, PhDView Slideset
SlidesetViral Hepatitis and Liver DiseaseSerum GP73 as a surrogate biomarker of significant liver fibrosis and cirrhosis in NAFLD- Fengmin LuView Slideset
SlidesetViral Hepatitis and Liver DiseaseFuture scenarios of algorithm building- Tom Travison, PhDView Slideset
SlidesetViral Hepatitis and Liver DiseaseA precision medicine approach to comprehensive NAFLD diagnosis via metabolomics-based liquid biopsy- Pablo OrtizView Slideset
SlidesetViral Hepatitis and Liver DiseaseNext-Generation Sequencing (NGS) of two independent cohorts identifies eleven circulating miRNAs for diagnosis of NASH and fibrosis- Sven FrancqueView Slideset
SlidesetViral Hepatitis and Liver DiseaseNavigating NASH biomarkers: From discovery to clinical practice- John Sninsky, PhDView Slideset
SlidesetViral Hepatitis and Liver DiseaseIntegrated assessment of diabetes, cardiovascular and liver risks and its potential application in the clinical management of NAFLD- Arun Sanyal, MD, MBBSView Slideset
